Fight Retinal Blindness! registry data: Ranibizumab and aflibercept safe for treating DME over 3 yearsAugust 18th 2022
The investigators retrospectively analyzed treatment-naive eyes with DME which received intravitreal treatment with either ranibizumab 0.5 mg or aflibercept 2 mg. All data were collected in the Fight Retinal Blindness! registry.
Perspectives on intravenous bevacizumab repackaged for intravitreal useJune 15th 2022
Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.